Graphite Bio's first drug program will target sickle cell anaemia based on innovations in DNA editing from Stanford University.

Escape Bio, a spinout of Gladstone Institutes, has secured the return of Osage University Partners, Novartis, Novo and Johnson & Johnson.

The Johns Hopkins spinout has raised cash from OUP as it looks to move its first candidate, targeting skin itch complications, into the clinic.

Wu Capital has led a series A round for Korro Bio, whose RNA editing technology was developed at UChicago-affiliated Marine Biological Laboratory.

University of Utah robotics spinout Sarcos has will use the funding for the commercial manufacturing of its industrial exoskeleton product.

Midea participated in a round for the speech processing technology provider, whose backers also include Tsinghua University's TusPark Ventures.

Leaps by Bayer co-led a $55m series A round for cancer immunotherapy developer Triumvira Immunologics, which was co-founded by McMaster's Jonathan Bramson.

Bill Gates has returned to lead an $85m round for satellite internet provider Kymeta, which has now raised more than $280m since it was set up to advance Duke University research.

UCSF spinout Mission Bio has pushed its overall funding to more than $120m following a series C round led by Novo Growth.

UChicago has returned for a $35m series B round for Kin Insurance, co-founded by an alumnus of the university’s Booth School of Business.